Bioactive lipids are essential components of human cells and tissues. As discussed in this review, the cancer lipidome is diverse and malleable, with the ability to promote or inhibit cancer pathogenesis. Targeting lipids within the tumor and surrounding microenvironment may be a novel therapeutic approach for treating cancer patients. Additionally, the emergence of a novel superfamily of lipid mediators termed specialized pro-resolving mediators (SPMs) has revealed a new role for bioactive lipid mediators in the resolution of inflammation in cancer biology. The role of SPMs in cancer holds great promise in our understanding of cancer pathogenesis and can ultimately be used in future cancer diagnostics and therapy.
Introduction
Bioactive lipids comprise a wide variety of molecules, whose biosynthesis and activity are responsible for several essential cell functions including cell wall integrity, cellular energy storage, and lipid signaling [1, 2] . Specific bioactive lipids often have pleiotropic and seemingly opposing activity. The biosynthesis of many lipids is dependent on the presence of other lipid precursors, and various lipids can regularly be exchanged within the cell. Recent studies on bioactive lipids in cancer emphasize the importance of understanding the cellular lipidome as an output of cellular function or cellular malignancy [3, 4] .
In 2003, LIPID MAPS (Lipid Metabolites and Pathways Strategy) [5] was initiated as a resource for studying the roles of individual and interacting lipids in cancer. Currently, there are over 37,000 known biologically active lipids and lipid-derived mediators [5] . The diversity of bioactive lipids is exemplified in their varied structures and functions (Fig. 1) . LIPID MAPS characterizes bioactive lipids into eight distinct families: fatty acyls (including fatty acids and eicosanoids), glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, polyketides, and saccharolipids. Certain bioactive lipids, such as glycerolipids and saccharolipids, have not been well characterized in a cancer setting. However, dysregulated signaling of fatty acyls, sphingolipids, glycerophospholipids, sterol lipids, and prenol lipids has been shown to contribute to cancer pathogenesis [6, 7] . Additionally, a novel super-family of omega-3 polyunsaturated fatty acid-derived lipid mediators termed specialized pro-resolving mediators (SPMs) has revealed a new role for bioactive lipids in the resolution of inflammation in cancer biology [8, 9] .
To date, many studies have focused on the association between the dysregulated lipidome and cancer progression. However, there remains a significant need, in most instances, for establishing molecular mechanisms to link the lipids and specific abnormal cellular phenotypes. Here, we will focus on the role of bioactive lipids in the pathogenesis and treatment of human cancers.
Fatty acyls
In the early 1930s, George and Mildred Burr demonstrated that fatty acids are essential dietary components [10] . Their studies recognized a deficiency disease in rats that could be rescued by supplementation with linoleic acid, a polyunsaturated omega-6 fatty acid. Polyunsaturated fatty acids (PUFAs), namely omega-6 and omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential dietary fatty acids that cannot be produced de novo by mammals. Most fatty acyls function as components of glycerophospholipids in cell membranes, dictating characteristics such as fluidity and permeability [11, 12] . Inhibiting a cell's ability to form new membranes, thereby blocking glycerophospholipid synthesis, could limit cell growth in tumors [13] .
The role of dietary fatty acids in cancer pathogenesis has become of recent public interest. However, the application of fatty acids in cancer therapy is more complex than simply elevated or decreased levels of omega-3 fatty acids or omega-6 fatty acids. Studies have demonstrated that cancer risk is not dependent on absolute omega-6 concentration in the diet, but rather the ratio between omega-6 and omega-3 fatty acids [14] . A western diet that is deficient in omega-3 fatty acids and abundant in omega-6 fatty acids has been linked to increased risk of developing prostate cancer [15] . A low ratio of omega-6 to omega-3 fatty acids prolongs hormone responsiveness of prostate cancer cells in vitro and may delay the progression of prostate cancer to a more malignant castration-resistant state in patients. The omega-6 to omega-3 ratio of 1.3:1, characteristic of an Asian diet, has been shown to be most effective in delaying prostate cancer cell progression [15] . Similarly, an omega-3 PUFA enriched diet can inhibit endometrial carcinoma tumor growth in a xenograft murine model by suppressing the activation and expression of critical proteins for cell cycle progression [16] . These preliminary studies provide possible mechanistic insight into the overall observations of omega-3 fatty acids' anti-tumor correlation. However, the role of omega-3 PUFA supplementation in patients is controversial. Brasky et al. demonstrated that patients with higher omega-3 PUFAs concentrations in their blood also had up to a 71% increased risk of developing prostate cancer [17] .
Assessment of cancer risk based on relative levels of fatty acyls has also been applied to other cancer types, such as colorectal cancer [18] . Specific fatty acyls are altered in various malignant tissues. In cancerous colorectal tissue, omega-6 fatty acids are elevated 1-to 3-fold, whereas the omega-3 fatty acids EPA and DHA are significantly reduced [18] . Variations in tissue fatty acyls may also provide indication of tumor grade. Omega-6 fatty acyls, linoleic acid, and arachidonic acid are increased in higher grade colorectal cancer, while the opposite holds true for detectable levels of omega-3 fatty acyls [18] . This distinct change in the bioactive lipids profile in colorectal cancer may be used as a potential biomarker for colorectal staging in the future.
Eicosanoids are derived from the fatty acyl arachidonic acid and are named for their 20-carbon backbone structure [1] . Prostaglandins, the first identified eicosanoids, were independently discovered by Drs. Von Euler and Goldblatt in 1935 [19] . In 1962, Drs. Bergstrom, Ryhage, and Samuelsson achieved the first structure elucidation of a prostaglandin (PGE 1 ) and later characterized its biosynthetic pathway [20] . In 1968, E.J. Corey completed the first total organic synthesis of prostaglandins including the E 1 and F 1 series [21, 22] . In the 1960s and 1970s, it was discovered that prostaglandins could be secreted by fibrosarcoma tumor cells [23, 24] . Prostaglandins were found to be directly responsible for bone reabsorption in organ culture, thus sparking interest in their potential role in cancer pathogenesis and associated hypercalcemia [25] [26] [27] . In 1971, Sir John Vane discovered that aspirinlike drugs could inhibit the synthesis of prostaglandins, for which he was awarded the 1982 Nobel Prize for Medicine along with Bengt Samuelsson and Sune Bergstrom [28] .
Both cyclooxygenases 1 and 2 (COX-1/2) biosynthesize prostaglandins from arachidonic acid. COX-1 is constitutively expressed in almost all tissues and additionally produces prostaglandins in platelets and the stomach lining, whereas COX-2 expression is limited to settings of acute inflammation [29] . Cyclooxygenase oxidizes arachidonic acid to produce prostaglandin G 2 (PGG 2 ), which is rapidly converted to prostaglandin H 2 (PGH 2 ). PGH 2 is a substrate for a subset of enzymes known as prostaglandin synthases. As PGH 2 is relatively unstable, it is often quickly metabolized into other prostaglandins including PGD 2 , PGE 2 , PGF 2 , and PGI 2 (prostacyclin). When PGH 2 is the substrate for thromboxane synthase, it is converted to thromboxane A 2 , (TXA 2 ), which is rapidly hydrolyzed to its biologically inactive metabolite thromboxane B 2 (TXB 2 ) [30] . Prostaglandins, PGI 2 , and thromboxane are collectively known as prostanoids. Prostanoids signal through G proteincoupled receptors (GPCRs), including DP, EP, FP, IP, and TP, designated for each prostanoid, PGD 2 , PGE 2 , PGF 2 , PGI 2 , and TXA 2 , respectively. The function of the vasculature, renal, and other systems depends on the balance and cooperation of prostanoids, as specific prostanoids can have opposing activity. In 1994, the DuBois laboratory discovered that COX-2 mRNA transcription is upregulated in human colorectal adenomas and adenocarcinomas [31] . This sparked interest in developing a therapeutic application for COX inhibitors in cancer.
Non-steroidal anti-inflammatory drugs (NSAIDs) bind and inhibit both COX isoforms with varying selectivity. NSAIDs, as well as selective COX-2 inhibitors (e.g., celecoxib), decrease endogenous eicosanoid production and associated pro-inflammatory signaling. Following the DuBois laboratory's seminal studies, clinical trials began evaluating COX inhibitor efficacy in various cancers. Initial clinical trials treating colon adenomas with celecoxib in patients with familial adenomatous polyposis (FAP) demonstrated a significant reduction in colorectal polyps in the celecoxib-treated group [32] . While COX inhibitors have been shown efficacious in treating many cancers, the mechanism by which they exert anti-tumor activity remains poorly understood. Previous studies have implicated decreased prostaglandin levels as the primary mechanism underlying COX inhibition and subsequent cancer suppression [33, 34] .
Prostaglandins
Prostaglandins (PGs) are pro-inflammatory prostanoids that promote the early stages of acute inflammation by enhancing edema and leukocyte infiltration. PGs are present at sensory nerve endings and thus also regulate the sensation of tenderness during acute inflammation. PGs have also been implicated in normal wound healing. Since the discovery that NSAIDs (including aspirin) could inhibit prostaglandin synthesis, the prostaglandin biosynthetic pathway has been the target for the development of novel anti-inflammatory agents.
Prostaglandins are often implicated in the initiation and propagation of cancer, providing a mechanistic link between inflammation and cancer. Prostaglandin E 2 (PGE 2 ) is widely recognized as a highly pro-oncogenic prostaglandin with downstream pro-tumorigenic activity, including the upregulation of angiogenic factors, anti-apoptotic factors, inflammatory chemokines, and immunosuppressive mediators [35] . Indeed, as early as the 1970s, it had been shown that prostaglandins are increased in colon tumors [36] and PGE 2 is increased in breast tumors [37] .
Early clinical studies targeting prostaglandins in cancer have focused on blocking cyclooxygenases' enzymatic activity [38] [39] [40] [41] . However, cyclooxygenase inhibitors, including NSAIDs or selective COX-2 inhibitors (i.e., celecoxib), have adverse side effects in the clinic due to the multiplicity of cyclooxygenase functions [42] [43] [44] . Vioxx and Celebrex, selective COX-2 inhibitor drugs, have since been taken off the market or limited in their use due to significant adverse effects on the vasculature [45] [46] [47] . Targeting the downstream pathways of PGE 2 function, as well as characterizing additional COX-mediated tumorigenic pathways, may provide new approaches to anti-PGE 2 therapy without disrupting the necessary roles of COX enzymes in vascular health.
Recent studies have focused on PGE 2 's role in other cancers, such as brain tumors. Altering PG metabolism in gliomas successfully reduces cell proliferation and increases apoptosis [48] . PGE 2 also induces IL-8 expression in astrocytomas, which in turn stimulates tumor-promoting inflammation and angiogenesis [49] . Conversely, inhibition of prostaglandin synthesis via pharmacological COX inhibition decreases tumor progression in a neuroblastoma murine model [50] . As brain tumors are among the most difficult cancers to treat, understanding this area of lipidomics may prove critical to the development of future therapies.
While PGE 2 is often associated with tumorigenesis, its direct effects on tumor cells remain poorly understood. PGE 2 is now known to be a key mediator of the autocrine and paracrine signaling pathways responsible for driving carcinoma cells towards a cancer stem cell-like state [51] . Carcinoma cells release IL-1, which induces COX-2 and mPGE 2 expression in attracted mesenchymal stem cells (MSCs) [51] . The PGE 2 produced by MSCs acts in an autocrine fashion to stimulate production of pro-tumorigenic cytokines, including IL-6, IL-8, GROα, and RANTES. Moreover, PGE 2 also acts in a paracrine manner on carcinoma cells to increase invasiveness, thereby creating a tumor-initiating cell population within a primary carcinoma [51] . Beginning in the 1960s, primary tumor growth was discovered to be dependent on tumor stroma [52] . Today, PGE 2 within the tumor stroma has been shown to be a potent inhibitor to the epithelial-mesenchymal transition, thereby inhibiting tumor pathogenesis [53] .
Following local invasion, cancerous cells spread to distant tissues through a complex series of events known as metastasis [54] . Many interrelated variables must cooperate for metastasis to take place, including changes to the tumor stroma and microenvironment [54] . Often, tumors metastasize to lymph nodes and other distant organs through the lymphatic system. There is now a known link between prostaglandins and lymphatic-driven metastasis, of which a key step is the growth of new lymphatic vessels (lymphangiogenesis) stimulated by vascular endothelial growth factor D (VEGF-D). The downregulation of 15-hydroxyprostaglandin dehydrogenase (PGDH), a PGE 2 metabolizing enzyme, and the subsequent increase in endogenous PGE 2 has been shown to accompany VEGF-D-driven metastasis [55] . This finding could provide insight into the role of PGs in metastasis. Eicosanoids, including prostaglandins, are characteristically autocrine and paracrine factors, and their pro-metastatic activity is thus due to changes in the local tumor microenvironment. PGE 2 also promotes invasion by certain kidney cancer cells by prostaglandin receptor (EP2 and EP4)-mediated AKT and RalA activation [56, 57] . In sum, PGE 2 contributes to multiple mechanisms of tumor metastasis.
Cancer stems cells (CSCs) are at the forefront of tumor pathogenesis and recurrence research. PGE 2 levels in human colorectal carcinoma tumors have been shown to positively correlate with CSC markers. Additionally, mice inoculated with colorectal carcinoma tumor cells and then subsequently treated with PGE 2 demonstrate increased metastases and tumor nodules. When these colonic tumors are isolated and cultured ex vivo, they demonstrate CSC characteristics [58] . CSCs have also been implicated in chemo-resistance, as they are able to survive cytotoxic therapy and subsequently repopulate the tumor. Bladder CSCs acquire chemo-resistance via PGE 2 released from neighboring apoptotic cells, suggesting pro-inflammatory lipids may play integral roles in the survival and outgrowth of CSCs [59] . As chemo-resistance continues to be an ongoing obstacle in current cancer therapies, targeting such lipids may prove critical for the development of novel CSC-targeting treatments.
Unlike PGE 2 , the role of prostaglandin D 2 (PGD 2 ) in carcinogenesis is less established. PGD 2 is an early antiinflammatory signaling molecule primarily produced by mast cells and plays a role in allergy-associated inflammation [60, 61] . A deficiency in PGD 2 synthase (H-PGDS), expressed by tumor-infiltrating mast cells, results in increased Lewis Lung carcinoma angiogenesis and tumor progression in mice, implicating PDG 2 as an anti-tumorigenic prostaglandin [62] . Additionally, loss of PGD 2 synthase results in increased TNFα expression and release by tumor-associated stromal cells, confirming a direct link between PGD 2 and tumor progression mediated through stromal signaling [62] .
The anti-tumor effects of PGD 2 can also be mediated by its downstream metabolite, 15-deoxy-(d12,14)-prostaglandin J 2 (15d-PGJ 2 ). 15d-PGJ 2 is a dehydration product of PGD 2 and directly binds PPARγ to inhibit inflammatory responses [63] . Recent studies, however, have shown that 15d-PGJ 2 has cytotoxic effects in renal cell carcinomas through a PPARγ-independent mechanism [64] . 15d-PGJ 2 also induces tumor cell apoptosis through a caspase-3-mediated pathway [65] [66] [67] . Thus, PGD 2 's anti-tumor activity may be enacted both indirectly through targeting the tumor microenvironment and directly through inducing tumor cell apoptosis.
Prostacyclin
Prostacyclin (PGI 2 ), like other prostaglandins, is biosynthesized from the energetically unstable PGH 2 . PGI 2 is a powerful vasodilator, inhibits thrombogenesis, and shares some parallel functions with PGE 2 , including pain response and renal function [68, 69] . In fact, metabolism of arachidonic acid by COX-2 to prostacyclin and PGE 2 is favored over the production of other prostaglandins [70] . Although endogenous prostacyclin is relatively unstable, prostacyclin analogues have been demonstrated to activate PPAR receptors [71, 72] . PPARδ has been shown to be upregulated in colon cancer through the administration of prostacyclin [73, 74] . Indeed, inhibition of prostacyclin biosynthesis and subsequent decreased PPARδ activation have been implicated in inducing cancer cell apoptosis [75] . Therefore, PGI 2 's effects on the vasculature, pain, renal function, apoptosis, and even cancer may be mediated through a microRNA-mediated mechanism.
Prostacyclin's translation into the clinic as a lipid biomarker has had some recent advances. Increased prostacyclin synthase (PGIS) correlates with decreased overall survival in breast cancer patients [76] . By contrast, increased PGIS has also been shown to correlate with prolonged survival in patients with head and neck squamous cell carcinomas receiving radiation therapy [77] . Prostacyclin is known in the clinic as epoprostenol and is often prescribed to patients with pulmonary hypertension, as it has been shown to prolong survival [78] . PGI 2 is primarily studied within the context of pulmonary hypertension, as PGI 2 and its analogues improve cardiopulmonary hemodynamics via lowering pulmonary arterial pressure and pulmonary vascular resistance [78] . Because prostacyclin is cardioprotective, prostacyclin-based therapeutics may exhibit less toxicity and cardiovascular side effects compared to paradigm cancer therapeutics, such as high-dose chemotherapy [79] . Further, iloprost, a synthetic derivative of prostacyclin, has been shown to exhibit chemopreventive activity in lung cancer [80] . However, prostacyclin is not an ideal choice for prostanoid-based tumor therapy as the PGI 2 receptor (IP) is highly expressed by both mouse and human tumor endothelial cells. Prostacyclin secretion is also higher in tumor endothelial cells compared to normal endothelial cells [81] . Therefore, PGI 2 could promote tumor angiogenesis in an autocrine manner, based on its known roles in vascular growth and function. However, it has been shown that pharmacologically blocking tumor endothelial cell IP can reduce endothelial cell migration and tube formation [81] . Although prostacyclin could mitigate the cardiotoxic side effects induced by chemotherapy, its proangiogenic activity may be an inherent limitation to its use in cancer therapy.
Thromboxane
The final member of the prostanoid family of eicosanoids is thromboxane, specifically thromboxane A 2 (TXA 2 ). TXA 2 is a potent vasoconstrictor and has been well studied in platelet activation. TXA 2 is also a vascular smooth muscle cell mitogen that can increase bronchoconstriction and serve as a physiological antagonist of prostacyclin. The thromboxane receptor, TP, is a seven trans-membrane G protein-coupled receptor (GPCR) able to couple with different G-proteins, including G q [82, 83] . TP has two splice variants, TPα and TPβ, with TPα having a more prominent role in thromboxane function in disease [84] .
Several recent studies have examined the mechanism of TP-regulated tumor growth. TPα induces VEGF gene expression in tumors, which may lead to primary tumor growth and metastasis. In lung cancer, 4-methylnitrosamino-1-3-pyridyl-1-butanone (NNK), a carcinogen present in cigarette smoke, stimulates TXA 2 production and receptor expression in lung cancer [85] . While cigarette smoke has been long known to increase COX-2 and PGE 2 expression in epithelial cells, the activation of TXA 2 is a novel mechanism for lung cancer cell growth. Blocking TXA 2 using a receptor antagonist decreases lung tumor cell proliferation and survival by inducing apoptosis [86] . TXA 2 has also been shown to promote invasion of lung cancer cells by increasing monocyte chemo-attractant protein-1 (MCP-1) through a TP-mediated signaling mechanism [87] . Increased protein levels of MCP-1 by tumor cells increases macrophage invasion by chemotaxis [87] . In addition to a downstream chemo-attractive effect on inflammatory cells, TP also regulates tumor colony formation [88] . TPα function is necessary for the P-selectin-mediated interaction between tumor cells, platelets, and endothelial cells in the lung. Thromboxane receptor knockout mice exhibit reduced metastases in a lung cancer model [88] .
Generally, prostanoids have been shown to have pro-tumor activity and are implicated in pathways that control both primary tumor growth and metastasis. Blocking prostanoid production in tumor and stromal cells may be a useful component of cancer therapy, if the adverse side effects observed from the use of COX-2 inhibitory drugs can be avoided.
Eicosanoid biomarkers
Lipids and lipid signaling are recent additions as therapeutic targets. Most lipid signaling is through GPCRs, and thus, targeted therapeutics have focused on agonists and antagonists to these receptors to elicit various lipid-based responses [89] . Biomarkers in cancer patients may prove useful for personalized treatment and be of particular importance in characterizing malignancy. Specifically, new research has suggested that eicosanoids may be useful as biomarkers indicating tumor presence or cancer progression.
For some time now, it has been known that lipid profiles of biological fluids can be compared via LC-MS-MS-based analysis. Patients with prostate cancer and patients with benign prostatic hyperplasia have distinctly different compositional ratios of fatty acids in their blood plasma, suggesting lipidomics could provide diagnostic markers or be used to identify high-risk patient populations [90] . Further, the overdiagnosis of cancer in the clinic is common, leading to unnecessary tests and treatments and subsequent unnecessary risks to patients. Through analysis of patient plasma by LC-ESI-MS-MS (electrospray ionization), a recent study established a lipid profile that can distinguish between benign and earlystage cancerous breast tumors [91] .
Lipid biomarkers can also be measured in patient urine samples. PGE-M, a stable metabolite of PGE 2 , directly correlates with inflammation in patients and is detectable in urine. Clinical studies have shown that PGE-M found in urine of breast cancer patients correlates with increased lung metastases [92] . Further, patients with lung metastases who have taken NSAIDs have significantly lower PGE-M levels than patients who have not taken any NSAIDs. Increased PGE-M levels are also found in women who have received cytotoxic chemotherapy, and could therefore serve as a potential biomarker for therapy-induced inflammation [92] . There is also a positive correlation between urinary PGE-M levels and breast cancer risk in postmenopausal women not on a consistent NSAID regiment [92, 93] . PGE 2 and PGE-M levels could thus also be used to identify high-risk populations for breast cancer [93] . Urinary biomarkers are especially of interest as the methods of measuring them are non-invasive and less stressful for patients than drawing many blood samples.
By understanding how COX-derived lipid metabolites contribute to cancer progression, we may be able to apply new approaches to establish novel cancer therapies that block prostanoid signaling. Success in this field must be dependent on selectively blocking certain prostanoids, such as PGE 2 , while retaining the functions of non-tumor-promoting prostanoids. By studying how prostanoids affect different cell types within the tumor microenvironment, future cancer diagnostics and therapies can apply this knowledge to make cancer lipidomics more effective and broadly applicable in the clinic.
Sphingolipids
Similar to the balance between omega-3 and omega-6 fatty acids in cancer cells, the ratio of sphingolipids to their metabolites, rather than their levels alone, regulates cell functions. The most well-studied sphingolipids are ceramides and sphingosines. Within the cancer field, ceramide metabolite ceramide-1-phosphate (C1P) and sphingosine metabolite sphingosine-1-phosphate (S1P) have been well characterized. Sphingolipids have already been implicated in many cellular processes necessary for cancer progression, notably in tumor cell proliferation and regulation of apoptosis [94] [95] [96] [97] .
Ceramide alone, without being converted to C1P, induces cell death by apoptosis. Cyclopamine, a known inducer of apoptosis and inhibitor of sonic hedgehog, increases endogenous ceramide production in human medulloblastoma cells via neutralizing sphingomyelin phosphodiesterase (nsMase), a member of the mammalian sphingomyelin phosphodiesterase family [98] . This is a novel off-target effect of cyclopamine, as knockdowns of known downstream targets of cyclopamine do not rescue cell survival [98] . Vitamin D3 and its analogues, shown to inhibit tumor cell proliferation, also block ceramide kinase (CerK) expression in neuroblastoma models resulting in an increased ratio of ceramide to C1P. This demonstrates that ceramide and C1P signaling play a role in the anti-proliferative activity of vitamin D3. Vitamin D3 also decreases protein levels of CerK via protein degradation [99] . Sphingolipid metabolites are inter-convertible; hence, their effects on cells are more dependent on the variations in the ratio between the phosphorylated and non-phosphorylated metabolites rather than the absolute levels of either. This is recognized as the rheostat model for sphingolipids, which can be used to evaluate the behavior of multiple types of bioactive lipids in cancer.
Continued studies are required to fully understand the signaling role of ceramide and C1P in cancer, as many ceramideinteracting proteins are only just being discovered. In fact, 97 unique short-chain C6-ceramide-binding proteins in human Schwannoma cells have recently been identified [100] . The largest cluster of these newly identified binding proteins are involved in gene transcription and protein synthesis, while a second cluster of proteins are involved in metabolic processes. The identification of novel ceramide-interacting proteins could enable us to delineate how ceramide regulates cell survival and apoptosis, and thus how they can be applied in anticancer therapeutics. For example, C18-ceramide has already been termed Bthe tumor suppressor lipid^ [100, 101] .
Ceramide's previously identified protein targets include cRaf, KSR, cathepsin D, and protein kinase C-ζ, CERT, and I2PP2A, an inhibitor of protein phosphatase 2A. Interactions of ceramide with these known protein partners have been widely studied and reviewed [102] [103] [104] . Ceramide analogues, inhibitors of ceramide degradation, and ceramide nanoliposomes have been shown to increase accumulation of intracellular ceramide in tumor cells, in turn inducing proapoptotic pathways [105] [106] [107] . Thus, ceramide may be a potential therapeutic target. However, the use of ceramide in cancer therapy has only proven mildly effective in the clinic due to challenges with delivering these hydrophobic and insoluble molecules [108] . Pegylated nanoliposomes could eliminate these issues and make ceramide more clinically effective as an anti-cancer therapy.
Like ceramide, sphingosine can be phosphorylated to generate sphingosine-1-phosphate (S1P) by the activity of two identified sphingosine kinases (SphK1 and SphK2). The bioactivity of S1P is most notably associated with its ability to stimulate cytoskeleton remodeling [109, 110] . Levels of S1P and SphK directly correlate with clinical prognosis and targeted therapy (tamoxifen) resistance in breast cancer [111] . Sphingosine kinase inhibitors have further been found to prevent actin rearrangement, a characteristic of aggressive breast cancer cells. This suggests that sphingosine kinase inhibitors could be a novel addition to traditional breast cancer therapy [112] . Nevertheless, there has been conflicting data with the use of selective SphK1 or SphK2 inhibitors to suppress primary tumor growth, and therefore, further studies are required for incorporating these inhibitors into the clinic.
Cellular localization is another important component of S1P's function in cancer cells. Nuclear localization of S1P and SphK1, concurrent with other signaling proteins, is indicative of a more aggressive estrogen receptor positive breast cancer and associated shortened survival [113] . One suggested mechanism for the observed pro-tumorigenic effect is that SphK1 signaling aids tumor cells in regulating Warburg metabolism [114] . The Warburg hypothesis, postulated by Nobel laureate Otto Heinrich Warburg, states that cancer pathogenesis is driven by dysregulation of cellular metabolism [115] . SphK1 stabilizes c-Myc, presumably via increased levels of intracellular S1P, maintaining Warburg metabolism and thus cancer cell survival [114] . S1P is upregulated in colon carcinogenesis, resulting in the induction of COX-2 expression [116] . Increased COX-2 expression, and subsequent altering of arachidonic acid metabolism, has been identified in many cancers and has been well reviewed [117] . More recently, S1P has been observed to have a regulatory role in other aspects of the tumor microenvironment, including angiogenesis and lymphangiogenesis [118] . Circulating levels of S1P have also been shown to correlate with tumor burden in a breast cancer implantation model [118] . In this model, S1P enhanced angiogenesis and lymphangiogenesis independent of alterations in VEGF-A and VEGF-C, the primary growth factors associated with these types of tumor lymphatic vessel growth [118] . This could imply that S1P may have non-tumor cell, autonomous effects on tumor growth, thereby revealing new perspectives through which S1P can be understood in the context of cancer.
Glycerophospholipids
Lysophospholipids are a type of glycerophospholipid within the chemical subclass of monoacylglycerophosphates. Like S1P, lysophospholipids regulate cell death and proliferation through GPCR signaling. Lysophosphatidic acid (LPA), a lysophospholipid, is an extracellular signaling molecule secreted by neurons, adipocytes, and cancer cells. The primary mechanism for LPA signaling, as well as other lysophospholipids, is via cell surface GPCRs, namely LPA [1] [2] [3] [4] [5] [6] . The expression and variations of these receptors differ between cell types, allowing for cell-type specific signaling.
LPA has been studied as a pro-metastatic lipid, as it regulates cell chemotaxis and invasion. LPA also activates small GTPases, such as Rho, Rac, and Cdc42, which also affect cell morphology and motility. RhoA and Rac1 have been shown to be independent effectors of LPA activation in ovarian cancer cells, together enhancing cell migration speed and controlling directionality [119] . The six known LPA receptors have diverse roles in the motility of cancer cells, including increased VEGF production, increased extracellular matrix deposition, and matrix metalloproteinases expression in addition to RhoA-and Rac1-mediated changes in migration [120] . Specific cancer types have distinct expression profiles of LPA receptors, with some receptors more commonly expressed in certain cancers [121] . In head and neck squamous cell carcinoma, expression of the receptor LPA 4 modulates, rather than enhances, tumor cell malignancy, suggesting LPA modifications as a potential approach to targeted tumor therapy [122] . The motility of gastric cancer cells requires LPA 2 receptor activation, whereas induced motility of liver epithelial cells function through increased expression of LPA 3 [123] . Given this heterogeneity in LPA receptor expression, further elucidation of distinct LPA profiles in cancer may provide valuable insights for the development of novel biomarkers and targeted cancer therapies.
Not all LPA-mediated tumor growth is via increased cell motility. LPA also has pro-tumorigenic potential by limiting immune cell surveillance, allowing tumor cells to evade detection by the circulating immune cells. Activation of the LPA 5 receptor on CD8+ T cells inhibits T cell activation, linking increased systemic LPA levels with suppressed immune responses in cancer [124] . In summary, LPA exerts pro-tumorigenic effects by stimulating tumor cell chemotaxis and invasion, as well as mediating immunosuppression.
Glycerolipids
Dysregulation of dietary lipids, such as the glycerolipids known as triglycerides, has been most notably associated with obesity. Obesity has become a dominating epidemic, affecting at least one in three Americans [125] . Obesity has been invariably linked to increased risk of numerous different cancers [126] [127] [128] [129] . Epidemiological studies have linked increased levels of triglycerides and cholesterol to risk of gastrointestinal, breast, endometrial, renal, and many other cancers [130] [131] [132] [133] [134] . Additionally, renal cell carcinoma has been found to have a lipidomic signature characteristic of increased cholesterol ester and triglycerides [135] . The cholesterol metabolite 27-hydroxycholesterol has been found to be a partial agonist for the estrogen receptor, and can increase ER-dependent tumor growth and metastasis in murine models of breast cancer [136] . However, a definitive association between circulating triglycerides and cancer remains to be established. As continued research efforts reveal the increased risk of diseases, particularly cancer, associated with obesity, characterization of these associated mechanisms is especially important for overall public health.
Prenol lipids
The majority of studies on prenol lipids in cancer have focused on the incorporation of specific prenol lipids in the diet. Fatsoluble vitamins E and K are categorized as prenol lipids. While dietary intake of the antioxidant vitamin E has been shown to be inversely proportional to gastric cancer risk, no such correlation is found between circulating blood levels of the vitamin with gastric cancer [137] . Thus, present studies of this prenol lipid in cancer have been mainly inconclusive. Other dietary antioxidants, including vitamin C, β-carotene, and α-carotene have also been associated with decreased gastric cancer risk, yet circulating blood levels did not exhibit a similar correlation [137] . These studies imply that effective antioxidants are not found freely circulating and provide potential insight into chemopreventive dietary changes. Alternatively, clinical trials have demonstrated vitamin E supplementation alone was associated with increased risk of prostate cancer by a significant margin [138] . Antioxidants like vitamin E may also accelerate lung cancer progression [139] . Further mechanistic studies on the role of prenol lipids in cancer are necessary, especially with growing public interest in the optimization of diet for cancer prevention.
Vitamin K, also a fat-soluble vitamin and prenol lipid, has been primarily studied for its role in blood coagulation. Vitamin K antagonists are anti-coagulants that have been used in the treatment of venous thromboembolism and heart disease. Increased dietary intake of vitamin K has been inversely correlated with cancer mortality risk [140] . The possible use of this prenol lipid in conjunction with other cancer therapies has not yet been studied.
Another chemopreventive dietary trend has focused on the Mediterranean diet, with an interest in the health benefits of extra virgin olive oil. One of the primary components of olive oil is squalene, a C30 isoprenoid lipid. Isoprenoids can generally be precursors to cholesterol via biosynthesis localized to peroxisomes and the endoplasmic reticulum [141] . Besides its function as a signaling molecule, squalene has also recently been introduced as a delivery system for other drugs via its role in constructing nanoparticles [142] . The health benefits of squalene could have additive benefit to pro-drug nanoparticles. Squalene-based nano-assemblies have the advantage of high drug payload, decreased toxicity, improved therapeutic response, as well as being biocompatible and easily prepared [143] [144] [145] . This approach to drug delivery has already demonstrated efficacy in the delivery of gemcitabine in colon cancer and leukemia murine models [144, 145] .
Polyketides
Finally, polyketides, particularly those produced by bacteria, have been used for many years in cancer therapy due to their cytotoxic effects in mammals. To date, over 450 molecules produced by marine cyanobacteria in coral reef ecosystems have been identified. Several of these compounds have anti-cancer and neurotoxic properties [146] [147] [148] . Polyketides offer a potential alternative therapy for cancers that have become resistant to chemotherapy [149, 150] . The most frequent cause of multidrug resistance in cancer cells is decreased intracellular accumulation of drugs due to increased expression of efflux pumps. However, cytotoxicity due to jadomycin is independent of ABC (ATP-binding cassette) efflux transporters [150] . Mithramycin, a polyketide produced by Streptomyces plicatus, has also been shown to be anti-angiogenic and pro-apoptotic [151] . These examples demonstrate the potential for discovery of other novel bioactive lipids that are not endogenous to mammalian systems and their potential therapeutic benefit in human cancer.
Non-mammalian-derived bioactive lipids also play a role in cancer. For instance, certain commensal bacteria in the gut have been shown to promote colorectal cancer, and colondwelling Escherichia coli produces colibactin, a peptidepolyketide and DNA damaging toxin. Moreover, colibactin has been implicated in the development of colorectal tumors in murine models of colitis-associated colon cancer [152] . This suggests that targeting non-mammalian bioactive lipids could have potential therapeutic benefit in human cancer.
Specialized pro-resolving mediators
Inflammation resolution refers to the ending of an inflammatory response. The resolution of inflammation was once believed to be a passive process, one in which over time the dilution of acute inflammatory mediators brought inflammation to an end. However, we now know the resolution of inflammation is an active process [153, 154] . The resolution phase is promoted and mediated by local, endogenous specialized pro-resolving mediators (SPMs) [153, 154] . SPMs resolve inflammation via halting neutrophil trafficking, promoting macrophage phagocytosis of apoptotic cells, and counter-acting pro-inflammatory cytokines [8, 155, 156] . There are different families of SPMs, two of which we will highlight here-resolvins and lipoxins. The term resolvins was derived from resolution-phase interaction products. Resolvins are biosynthesized from precursor omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) [157, 158] , and their individual actions are mediated by GPCRs [157, 158] . Resolvin D1, 7S, 8R, 17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, and 19Z-docosahexaenoic acid are a series of resolvins derived from the oxygenation of DHA [159] (Fig. 1) . The synthesis of resolvin D1 occurs during the trafficking of leukocytes to the site of inflammation and is a product of transcellular biosynthesis between the neutrophils and endothelial cells [160] . Lipoxin A 4 (LXA 4 ) is another endogenous SPM derived from arachidonic acid. The structure of lipoxin A 4 , 5S, 6R, 15S-trihydroxy-7,9,13-trans-11-eicosatetraeoic acid demonstrates stereoselective properties at picogram to nanogram doses [161] . The potency of LXA 4 is associated with specific double bond isomerization, alcohol chirality, dehydrogenation of alcohols, and reduction of double bonds [156] . Similar to resolvins, lipoxins promote the resolution of inflammation by enhancing macrophage phagocytosis and countering pro-inflammatory mediators such as TNF-mediated cytokines and reactive oxygen species [156] . The role of omega-3 fatty acid-derived mediators, such as SPMs, in the treatment and prevention of inflammatory diseases has become increasingly of both academic and popular interest; more specifically, their role in cancer is rapidly emerging.
Hanahan and Weinberg defined inflammation as an enabling characteristic of tumor growth, meaning inflammation is needed for the process of tumorigenesis [162] . Unresolved inflammation is a major characteristic in the pathogenesis of many human diseases [153] . Inflammation is a hallmark of cancer and is a risk factor for many cancers and can even initiate cancer [163, 164] . The importance of inflammation in cancer was also elegantly demonstrated in a randomized double-blind trial in patients with atherosclerosis [165] . Patients who received canakinumab, an IL-1beta inhibitor marked for use in systemic inflammatory diseases, had significantly reduced lung cancer incidence and related mortality [165] .
Resolvins and their precursors have been shown to exhibit anti-tumor activity in oral cancer, gastric cancer, melanomas, pancreatic cancer, colon cancer, liver cancer, and lung cancer [166] [167] [168] [169] [170] . Additionally, the anti-tumorigenic mechanism has been demonstrated to be multi-modal, including targeting of angiogenesis, the epithelial-mesenchymal transition (EMT) and pro-tumorigenic cytokines, as well as enhancing natural killer cells and macrophages (Table 1) [168] [169] [170] [171] [172] . Resolvins enhance macrophage phagocytosis in many different inflammatory models, including inflammation associated with cancer therapies [9, 153] . Molecular mechanisms associated with the anti-tumor activity of resolvins are shown to be via inhibiting key oncogenic pathways. Downstream effects of resolvin D1 have demonstrated inhibition of c-Myc expression, NF-kB, and mTOR [168, 170, 173] .
Lipoxins have also demonstrated a role in cancer pathogenesis. Lipoxins have been implicated in pancreatic cancer, Kaposi's sarcoma, liver cancer, melanoma, papilloma, colon cancer, and even non-solid tumors, such as leukemia [174] [175] [176] [177] [178] [179] . Similar to resolvins, lipoxins also play a diverse role within the tumor microenvironment (Table 1 ) [174] [175] [176] [177] [178] . Inflammation within the tumor microenvironment, secondary to current cancer therapy, has been demonstrated to promote growth of dormant tumors resulting in tumor recurrence [9] . Thus, given their anti-inflammatory nature, resolvins hold promise as an adjuvant therapy to chemotherapy and radiation, which inherently induce inflammation within the tumor microenvironment and can in turn stimulate tumor growth [9] . Additionally, resolvins and lipoxins are non-toxic and non-immunosuppressive, key attributes that set SPMs apart from current cancer therapies that demonstrate severe side effects in patients. Maresins, another family of SPMs derived from DHA [180] , may also hold promise in understanding and manipulating the tumor microenvironment. The structure of maresin 1 (Mar1) is 7R,14S-dihydroxydocosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid (Fig. 1) . Aptly named from their function as macrophage mediators in resolving inflammation, maresins are not only involved in cellular trafficking during the acute inflammatory phase but have also demonstrated to play a role in tissue regeneration [181] . The potential role of maresins in cancer remains of interest.
Outlook
Bioactive lipids and their downstream metabolites are essential components of human cells and tissues. As discussed in this 
